The Elecsys Anti-SARS-CoV-2 antibody test from Roche, Basel, Switzerland, is now available at more than 20 commercial and hospital lab sites throughout the United States. The antibody test was granted an FDA emergency use authorization in early May. In the next several weeks, the company plans to increase test availability to more than 200 commercial and hospital lab sites, with the ability to perform millions of tests per week.
“Roche is proud to make this highly accurate serology test available in the United States to determine if a person has developed antibodies to covid-19,” says Matt Sause, president and chief executive officer of Roche Diagnostics North America. “Reliable, high-quality antibody testing is essential to help us overcome this pandemic and will play an important role in getting people back to work. We are proud to partner with LabCorp in making this test available in the United States.”
The Roche antibody test provides 99.8% specificity, which is crucial for determining reliably whether a person has been exposed to the virus and has developed antibodies.
“Our long-standing relationship and collaboration with Roche enables us to introduce many innovative, high-quality tests for clinicians and patients, which is more important now than ever before,” says Brian Caveney, MD, chief medical officer and president of LabCorp Diagnostics. “Roche’s new antibody test allows LabCorp to provide more options and increase covid-19 testing capacity as we support the country’s response to the health crisis.”
For more information, visit Roche.